Recent studies examining multiple myeloma samples have demonstrated that ~20% of patient samples harbor mutations or amplifications of genes whose protein products participate in either canonical or non-canonical NF-κB signaling pathways, leading to constitutive NF-κB activation [54,55]. Here, NFKB1 is linked to AL amyloidosis.